Le Lézard
Classified in: Health
Subject: FDA

Ampio Pharmaceuticals Provides Regulatory Update


ENGLEWOOD, Colo., April 29, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has received comments from the U.S. Food and Drug Administration (FDA) regarding their Special Protocol Assessment (SPA). The FDA recommended the Company not start their confirmatory trial without obtaining FDA concurrence on the trial design. The Company agreed with the comments they received from the FDA and immediately sent a revised SPA to the FDA for review.

Ampio Pharmaceuticals Logo.  (PRNewsFoto/Ampio Pharmaceuticals, Inc.) (PRNewsfoto/Ampio Pharmaceuticals, Inc.)

"While we will not officially start the trial until the SPA is approved," said CEO Michael Macaluso. "Extensive preparatory work is already underway. We hope to start the trial in May."

About Osteoarthritis
Osteoarthritis (OA) is an incurable and progressive disorder of the joints involving degradation of the intra-articular cartilage, joint lining, ligaments, and bone. Certain risk factors in conjunction with natural wear and tear lead to the breakdown of cartilage. Osteoarthritis is caused by inflammation of the soft tissue and bony structures of the joint, which worsens over time and leads to progressive thinning of articular cartilage. Other symptoms include narrowing of the joint space, synovial membrane thickening, osteophyte formation and increased density of subchondral bone.

About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company focused on the development of Ampiontm to treat prevalent inflammatory conditions for which there are limited treatment options.

Forward-Looking Statements
Ampio's statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's expectations with respect to Ampion and its classification, as well as those associated with regulatory approvals and other FDA decisions such as the SPA, whether the FDA will approve the same and the timing thereof, the Biological License Application (BLA), the ability of Ampio to enter into partnering arrangements for any of its products, including Ampion and Optina, clinical trials and decisions and changes in business conditions and similar events, all of which are inherently subject to various risks and uncertainties. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and other documents filed with the Securities and Exchange Commission. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact
Phone: (720) 437-6500
info@ampiopharma.com

SOURCE Ampio Pharmaceuticals, Inc.


These press releases may also interest you

at 07:15
The "Usher Syndrome Type 2 - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.  This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Usher...

at 07:10
Helius Medical Technologies, Inc. ("Helius" or the "Company") CEO Philippe Deschamps has been invited to brief the US Congress on the latest technologies, innovations and policies in clinical neuroscience at the 9th Annual Brain Mapping Foundation...

at 07:10
ReadCoor, Inc., a company leading true multi-omic spatial sequencing, today unveils its first product line, including multi-omic spatial sequencing assays and the RC2 instrument. The platform is powered by ReadCoor's proprietary FISSEQ (Fluorescent...

at 07:05
Rocket Pharmaceuticals, Inc. ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, announces the recent publication of a peer-reviewed manuscript: the first...

at 07:05
Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced that Anthony Johnson, M.D., President and Chief Executive Officer of...

at 07:05
Omeros Corporation today announced that the company will issue its fourth quarter and year-end 2019 financial results for the period ended December 31, 2019, on Monday, March 2, 2020, after the market closes. Omeros management will host a conference...



News published on 29 april 2019 at 08:00 and distributed by: